Altered neural and vascular mechanisms in hypertension

Physiological Research

Volumn 60, Issue 3, 2011, Pages 381-402

  Pinterova M ^a   Kunes J ^a   Zicha, J ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Alpha and beta adrenoceptors; Blood pressure; Calcium influx; Calcium sensitization; G proteins; L type voltage dependent calcium channels; Potassium channels; RhoA Rho kinase pathway; Spontaneously hypertensive rats; Sympathetic nervous system

Indexed keywords

EID: 79960936350     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932189     Document Type: Review

References (140)

1. ABEL PW, HERMSMEYER K: Sympathetic cross-innervation of SHR and genetic controls suggests a trophic influence on vascular muscle membranes. Circ Res 49: 1311-1318, 1981.
2. ALLEN AM: Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension 39: 275-280, 2002.
3. + channels in vascular smooth muscle during hypertension. J Clin Invest 112: 717-724, 2003.
4. AMER MS: Cyclic nucleotides in disease; on the biochemical etiology of hypertension. Life Sci 17: 1021-1038, 1975.
5. ANAND-SRIVASTAVA MB: Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition. Biochem J 288: 79-85, 1992.
6. ANAND-SRIVASTAVA MB: Atrial natriuretic peptide-C receptor and membrane signalling in hypertension. J Hypertens 15: 815-826, 1997.
7. ANTONACCIO MJ, KERWIN L: Pre- and postjunctional inhibition of vascular sympathetic function by captopril in SHR. Implication of vascular angiotensin II in hypertension and antihypertensive actions of captopril. Hypertension 3 (Suppl I): I54-I62, 1981.
8. + channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage. J Pharmacol Exp Ther 275: 775-783, 1995.
9. BALT JC, MATHY MJ, PFAFFENDORF M, VAN ZWIETEN PA: Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats. Fundam Clin Pharmacol 17: 83-91, 2003.
10. BENHAM CD, TSIEN RW: Noradrenaline modulation of calcium channels in single smooth muscle cells from rabbit ear artery. J Physiol Lond 404: 767-784, 1988.
11. BENHAM CD, HESS P, TSIEN RW: Two types of calcium channels in single smooth muscle cells from rabbit ear artery studied with whole-cell and single-channel recordings. Circ Res 61 (Suppl I): I10-I16, 1987.
12. BIRNBAUMER L, PEREZ-REYES E, BERTRAND P, GUDERMANN T, WEI XY, KIM H, CASTELLANO A, CODINA J: Molecular diversity and function of G proteins and calcium channels. Biol Reprod 44: 207-224, 1991.
13. BOLZ SS, VOGEL L, SOLLINGER D, DERWAND R, DE WIT C, LOIRAND G, POHL U: Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 107: 3081-3087, 2003.
14. BORKOWSKI KR, PORTER M: Beta-adrenoreceptor-mediated modulation of vasoconstriction in rat isolated perfused mesenteric arteries. J Auton Pharmacol 3: 275-279, 1983.
15. BUCHER B, HEITZ C, STOCLET JC: Age-related changes of in vivo beta-adrenergic responsiveness in normotensive and spontaneously hypertensive rats. Eur J Pharmacol 102: 31-37, 1984.
16. CABASSI A, VINCI S, CALZOLARI M, BRUSCHI G, BORGHETTI A: Regional sympathetic activity in prehypertensive phase of spontaneously hypertensive rats. Life Sci 62: 1111-1118, 1998.
17. CAMPBELL GR, CHAMLEY-CAMPBELL J, SHORT N, ROBINSON RB, HERMSMEYER K: Effect of crosstransplantation on normotensive and spontaneously hypertensive rat arterial muscle membrane. Hypertension 3: 534-543, 1981.
18. 2-adrenoreceptor-stimulated RhoA and Rho kinase in rat aorta. Am J Physiol 283: H1361-H1369, 2002.
19. CARVALHO MH, SCIVOLETTO R, FORTES ZB, NIGRO D, CORDELLINI S: Reactivity of aorta and mesenteric microvessels to drugs in spontaneously hypertensive rats: role of the endothelium. J Hypertens 5: 377-382, 1987.
20. CASSIS LA, STITZEL RE, HEAD RJ: Hypernoradrenergic innervation of the caudal artery of the spontaneously hypertensive rat: an influence upon neuroeffector mechanisms. J Pharmacol Exp Ther 234: 792-803, 1985.
21. CLAPHAM DE, NEER EJ: New roles for G-protein βγ-dimers in transmembrane signalling. Nature 365: 403-406, 1993.
22. + channels play a major role in mediating the vascular effects of iloprost and cicaprost. Eur J Pharmacol 356: 215-224, 1998.
23. CLOUGH DP, HATTON R, KEDDIE JR, COLLIS MG: Hypotensive action of captopril in spontaneously hypertensive and normotensive rats. Interference with neurogenic vasoconstriction. Hypertension 4: 764-772, 1982.
24. COX RH: Changes in the expression and function of arterial potassium channels during hypertension. Vascul Pharmacol 38: 13-23, 2002.
25. COX RH, RUSCH NJ: New expression profiles of voltage-gated ion channels in arteries exposed to high blood pressure. Microcirculation 9: 243-257, 2002.
26. DAMPNEY RA, COLEMAN MJ, FONTES MA, HIROOKA Y, HORIUCHI J, LI YW, POLSON JW, POTTS PD, TAGAWA T: Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin Exp Pharmacol Physiol 29: 261-268, 2002.
27. DAWES M, CHOWIENCZYK PJ, RITTER JM: Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation 95: 2293-2297, 1997.
28. DE CHAMPLAIN J: Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens 8 (Suppl 7): S77-S85, 1990.
29. -adrenoceptor stimulation in pithed normotensive rats. Naunyn Schmiedebergs Arch Pharmacol 321: 309-313, 1982.
30. DENDORFER A, RAASCH W, TEMPEL K, DOMINIAK P: Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 93 (Suppl 2): 24-29, 1998.
31. DERAGON G, REGOLI D, RIOUX F: The effects of vasodilators in the perfused hind limbs of spontaneously hypertensive and normotensive rats. Can J Physiol Pharmacol 56: 624-629, 1978.
32. 2-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. Gen Pharmacol 34: 101-106, 2000.
33. EARLEY S, BRAYDEN JE: Transient receptor potential channels and vascular function. Clin Sci 119: 19-36, 2010.
34. EIKENBURG DC: Effects of captopril on vascular noradrenergic transmission in SHR. Hypertension 6: 660-665, 1984.
35. ERDOS B, BROXSON CS, KING MA, SCARPACE PJ, TUMER N: Acute pressor effect of central angiotensin II is mediated by NAD(P)H-oxidase-dependent production of superoxide in the hypothalamic cardiovascular regulatory nuclei. J Hypertens 24: 109-116, 2006.
36. ESLER M, RUMANTIR M, KAYE D, JENNINGS G, HASTINGS J, SOCRATOUS F, LAMBERT G: Sympathetic nerve biology in essential hypertension. Clin Exp Pharmacol Physiol 28: 986-989, 2001.
37. FUKAMI Y, TOKI Y, NUMAGUCHI Y, NAKASHIMA Y, MUKAWA H, MATSUI H, OKUMURA K, ITO T: Nitroglycerin-induced aortic relaxation mediated by calcium-activated potassium channel is markedly diminished in hypertensive rats. Life Sci 63: 1047-1055, 1998.
38. 2-adrenergic receptors in hypertension. Am J Hypertens 14: 171S-177S, 2001.
39. 2+ release from sarcoplasmic reticulum is required for sustained TRPM4 activity in cerebral artery smooth muscle cells. Am J Physiol 299: C279-C288, 2010.
40. GRAF R, CODINA J, BIRNBAUMER L: Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding proteins. Mol Pharmacol 42: 760-764, 1992.
41. GRASSI G, CATTANEO BM, SERAVALLE G, LANFRANCHI A, MANCIA G: Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31: 68-72, 1998.
42. GRASSI G, QUARTI-TREVANO F, DELL'ORO R, MANCIA G: Essential hypertension and the sympathetic nervous system. Neurol Sci 29 (Suppl 1): S33-S36, 2008.
43. GUYENET PG: The sympathetic control of blood pressure. Nat Rev Neurosci 7: 335-346, 2006.
44. + channel in the relaxation of bovine tracheal smooth muscle by glyceryl trinitrate and sodium nitroprusside. J Pharmacol Exp Ther 262: 263-270, 1992.
45. HARDER DR, HERMSMEYER K: Membrane mechanisms in arterial hypertension. Hypertension 5: 404-408, 1983.
46. HARDER DR, CONTNEY SJ, WILLEMS WJ, STEKIEL WJ: Norepinephrine effect on in situ venous membrane potential in spontaneously hypertensive rats. Am J Physiol 240: H837-H842, 1981.
47. 2-adrenergic receptors in NTS facilitate baroreflex function in adult spontaneously hypertensive rats. Am J Physiol 282: H2336-H2345, 2002.
48. HEAD RJ: Hypernoradrenergic innervation: its relationship to functional and hyperplastic changes in the vasculature of the spontaneously hypertensive rat. Blood Vessels 26: 1-20, 1989.
49. HERMSMEYER K: Electrogenesis of increased norepinephrine sensitivity of arterial vascular muscle in hypertension. Circ Res 38: 362-367, 1976.
50. HILGERS RH, WEBB RC: Molecular aspects of arterial smooth muscle contraction: focus on Rho. Exp Biol Med (Maywood) 230: 829-835, 2005.
51. HUGHES AD: Calcium channels in vascular smooth muscle cells. J Vasc Res 32: 353-370, 1995.
52. ISHII H, ITOH K, NOSE T: Different antihypertensive effects of nifedipine in conscious experimental hypertensive and normotensive rats. Eur J Pharmacol 64: 21-29, 1980.
53. 2+ channels by cAMP and cGMP in vascular smooth muscle cells. Circ Res 73: 1128-1137, 1993.
54. JACKSON WF: Ion channels and vascular tone. Hypertension 35: 173-178, 2000.
55. JACKSON WF: Potassium channels in the peripheral microcirculation. Microcirculation 12: 113-127, 2005.
56. JOHANSSON P: Alpha-adrenoceptors: recent development and some comparative aspects. Comp Biochem Physiol C 78: 253-261, 1984.
57. JUDY WV, FARRELL SK: Arterial baroreceptor reflex control of sympathetic nerve activity in the spontaneously hypertensive rat. Hypertension 1: 605-614, 1979.
58. JUDY WV, WATANABE AM, MURPHY WR, APRISON BS, YU PL: Sympathetic nerve activity and blood pressure in normotensive backcross rats genetically related to the spontaneously hypertensive rat. Hypertension 1: 598-604, 1979.
59. K-LAFLAMME A, OSTER L, CARDINAL R, DE CHAMPLAIN J: Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. Hypertension 30: 278-287, 1997.
60. 2-adrenergic receptor signalling in hypertension. Clin Sci (Lond) 109: 431-437, 2005.
61. KAZDA S, GARTHOFF B, KNORR A: Interference of the calcium antagonist nisoldipine with the abnormal response of vessels from hypertensive rats to alpha-adrenergic stimulation. J Cardiovasc Pharmacol 7 (Suppl 6): S61-S65, 1985.
62. V1.2a,b) by protein kinases. Am J Physiol 281: C1743-C1756, 2001.
63. KOBINGER W: New concepts on alpha-adrenoceptors in pharmacology. J Pharmacol 15 (Suppl 1): 5-22, 1984.
64. KOST CK, JR., HERZER WA, LI PJ, JACKSON EK: Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 26: 449-455, 1999.
65. KUNEŠ J, HOJNÁ S, KADLECOVÁ M, DOBEŠOVÁ Z, RAUCHOVÁ H, VOKURKOVÁ M, LOUKOTOVÁ J, PECHÁNOVÁ O, ZICHA J: Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res 53 (Suppl 1): S23-S34, 2004.
66. LAPPAS G, DAOU GB, ANAND-SRIVASTAVA MB: Oxidative stress contributes to the enhanced expression of Giα proteins and adenylyl cyclase signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 23: 2251-2261, 2005.
67. LEDOUX J, WERNER ME, BRAYDEN JE, NELSON MT: Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 21: 69-78, 2006.
68. LEE DL, WEBB RC, JIN L: Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44: 796-799, 2004.
69. 2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J Biol Chem 272: 5063-5068, 1997.
70. LEWIS SJ, BHOPATKAR MY, WALTON TM, BATES JN: Role of voltage-sensitive calcium-channels in nitric oxide-mediated vasodilation in spontaneously hypertensive rats. Eur J Pharmacol 528: 144-149, 2005.
71. B receptors in autonomic control of systemic blood pressure. Adv Pharmacol 58: 257-286, 2010.
72. LI PL, ZOU AP, CAMPBELL WB: Regulation of potassium channels in coronary arterial smooth muscle by endothelium-derived vasodilators. Hypertension 29: 262-267, 1997.
73. LI XF, TRIGGLE CR: Effects of pertussis and cholera toxins on alpha-adrenoceptor function in rat tail artery: differences in hypertension. Can J Physiol Pharmacol 71: 791-799, 1993.
74. i proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats. Circ Res 91: 247-254, 2002.
75. LIU H, XIONG Z, SPERELAKIS N: Cyclic nucleotides regulate the activity of L-type calcium channels in smooth muscle cells from rat portal vein. J Mol Cell Cardiol 29: 1411-1421, 1997a.
76. + channels in aorta of hypertensive rats. Hypertension 30: 1403-1409, 1997b.
77. MAGEE JC, SCHOFIELD GG: Neurotransmission through sympathetic ganglia of spontaneously hypertensive rats. Hypertension 20: 367-373, 1992.
78. MAKARITSIS KP, JOHNS C, GAVRAS I, ALTMAN JD, HANDY DE, BRESNAHAN MR, GAVRAS H: Sympathoinhibitory function of the α2A-adrenergic receptor subtype. Hypertension 34: 403-407, 1999.
79. MARCIL J, ANAND-SRIVASTAVA MB: Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension. Mol Cell Biochem 149-150: 223-231, 1995.
80. MARCIL J, THIBAULT C, ANAND-SRIVASTAVA MB: Enhanced expression of Gi-protein precedes the development of blood pressure in spontaneously hypertensive rats. J Mol Cell Cardiol 29: 1009-1022, 1997.
81. 2+ channels to contractile responses in spontaneously hypertensive rat mesenteric arteries. Am J Hypertens 10: 1231-1239, 1997.
82. MILLIGAN G, KOSTENIS E: Heterotrimeric G-proteins: a short history. Br J Pharmacol 147 (Suppl 1): S46-S55, 2006.
83. MORIMOTO S, SASAKI S, MIKI S, KAWA T, ITOH H, NAKATA T, TAKEDA K, NAKAGAWA M: Pressor response to pulsatile compression of the rostral ventrolateral medulla mediated by nitric oxide and c-fos expression. Br J Pharmacol 129: 859-864, 2000.
84. MUKAI Y, SHIMOKAWA H, MATOBA T, KANDABASHI T, SATOH S, HIROKI J, KAIBUCHI K, TAKESHITA A: Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 15: 1062-1064, 2001.
85. NAGUMO H, SASAKI Y, ONO Y, OKAMOTO H, SETO M, TAKUWA Y: Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol 278: C57-C65, 2000.
86. NELSON MT, QUAYLE JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268: C799-C822, 1995.
87. NELSON MT, WORLEY JF: Dihydropyridine inhibition of single calcium channels and contraction in rabbit mesenteric artery depends on voltage. J Physiol Lond 412: 65-91, 1989.
88. NELSON MT, STANDEN NB, BRAYDEN JE, WORLEY JF, III: Noradrenaline contracts arteries by activating voltage-dependent calcium channels. Nature 336: 382-385, 1988.
89. NEVES SR, RAM PT, IYENGAR R: G protein pathways. Science 296: 1636-1639, 2002.
90. NILSSON H: Interactions between membrane potential and intracellular calcium concentration in vascular smooth muscle. Acta Physiol Scand 164: 559-566, 1998.
91. 2+ channels in resistance arteries from spontaneously hypertensive rats. Circ Res 73: 1090-1099, 1993.
92. OHYA Y, TSUCHIHASHI T, KAGIYAMA S, ABE I, FUJISHIMA M: Single L-type calcium channels in smooth muscle cells from resistance arteries of spontaneously hypertensive rats. Hypertension 31: 1125-1129, 1998.
93. OKAMOTO K, AOKI K: Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27: 282-293, 1963.
94. 1-adrenoceptors up-regulation accompanied by the impairment of beta-adrenergic vasodilatation in hypertension. J Pharmacol Exp Ther 328: 982-990, 2009.
95. ORLOV SN, POSTNOV YV: Calcium accumulation and calcium binding by the cell membranes of cardiomyocytes and smooth muscle of aorta in spontaneously hypertensive rats. Clin Sci (Lond) 59 (Suppl 6): 207s-209s, 1980.
96. 2+ influx in vascular smooth muscle cells. Hypertension 27: 774-780, 1996.
97. OSBORN JW: Hypothesis: set-points and long-term control of arterial pressure. A theoretical argument for a long-term arterial pressure control system in the brain rather than the kidney. Clin Exp Pharmacol Physiol 32: 384-393, 2005.
98. OUSTERHOUT JM, SPERELAKIS N: Cyclic nucleotides depress action potentials in cultured aortic smooth muscle cells. Eur J Pharmacol 144: 7-14, 1987.
99. PANDEY SK, ANAND-SRIVASTAVA MB: Modulation of G-protein expression by the angiotensin converting enzyme inhibitor captopril in hearts from spontaneously hypertensive rats. Relationship with adenylyl cyclase. Am J Hypertens 9: 833-837, 1996.
100. PAULIS L, LÍŠKOVÁ S, PINTÉROVÁ M, DOBEŠOVÁ Z, KUNEŠ J, ZICHA J: Nifedipine-sensitive noradrenergic vasoconstriction is enhanced in spontaneously hypertensive rats: the influence of chronic captopril treatment. Acta Physiol (Oxf) 191: 255-266, 2007.
101. 2+ channels: is membrane depolarization the signal? Circ Res 94: e97-104, 2004.
102. 2 are not mutated. Circ Res 79: 974-983, 1996.
103. PINTÉROVÁ M, LÍŠKOVÁ S, DOBEŠOVÁ Z, BEHULIAK M, KUNEŠ J, ZICHA J: Impaired control of L-type voltage-dependent calcium channels in experimental hypertension. Physiol Res 58 (Suppl 2): S43-S54, 2009.
104. PINTÉROVÁ M, KAREN P, KUNEŠ J, ZICHA J: Role of nifedipine-sensitive sympathetic vasoconstriction in maintenance of high blood pressure in spontaneously hypertensive rats: effect of Gi-protein inactivation by pertussis toxin. J Hypertens 28: 969-978, 2010.
105. 2+-entry and limit its diffusion into vascular smooth muscle cells. Cell Calcium 40: 359-371, 2006.
106. 2+ channels in mesenteric and skeletal arteries of SHR. Hypertension 40: 214-219, 2002.
107. RAASCH W, DOMINIAK P, ZIEGLER A, DENDORFER A: Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension 44: 346-351, 2004.
108. RICHER C, DOUSSAU MP, GIUDICELLI JF: Influence of captopril and enalapril on regional vascular alphaadrenergic receptor reactivity in SHR. Hypertension 6: 666-674, 1984.
109. ROSS CA, RUGGIERO DA, PARK DH, JOH TH, SVED AF, FERNANDEZ-PARDAL J, SAAVEDRA JM, REIS DJ: Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin. J Neurosci 4: 474-494, 1984.
110. 2+ channels by cyclic nucleotide cross activation of opposing protein kinases in rabbit portal vein. Circ Res 82: 557-565, 1998.
111. SADOSHIMA J, AKAIKE N, KANAIDE H, NAKAMURA M: Cyclic AMP modulates Ca-activated K channel in cultured smooth muscle cells of rat aortas. Am J Physiol 255: H754-H759, 1988.
112. SANDER M, VICTOR RG: Neural mechanisms in nitric-oxide-deficient hypertension. Curr Opin Nephrol Hypertens 8: 61-73, 1999.
113. SANDERS KM: Invited review: mechanisms of calcium handling in smooth muscles. J Appl Physiol 91: 1438-1449, 2001.
114. 2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 275: 21722-21729, 2000.
115. SCHLAICH MP, LAMBERT E, KAYE DM, KROZOWSKI Z, CAMPBELL DJ, LAMBERT G, HASTINGS J, AGGARWAL A, ESLER MD: Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43: 169-175, 2004.
116. SCORNIK FS, CODINA J, BIRNBAUMER L, TORO L: Modulation of coronary smooth muscle KCa channels by Gsα independent of phosphorylation by protein kinase A. Am J Physiol 265: H1460-H1465, 1993.
117. SIFFERT W: G-protein β3 subunit 825T allele and hypertension. Curr Hypertens Rep 5: 47-53, 2003.
118. SIFFERT W, ROSSKOPF D, MORITZ A, WIELAND T, KALDENBERG-STASCH S, KETTLER N, HARTUNG K, BECKMANN S, JAKOBS KH: Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 96: 759-766, 1995.
119. SIFFERT W, ROSSKOPF D, SIFFERT G, BUSCH S, MORITZ A, ERBEL R, SHARMA AM, RITZ E, WICHMANN HE, JAKOBS KH, HORSTHEMKE B: Association of a human G-protein β3 subunit variant with hypertension. Nat Genet 18: 45-48, 1998.
120. SOMLYO AP, SOMLYO AV: Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol Lond 522: 177-185, 2000.
121. SONKUSARE S, PALADE PT, MARSH JD, TELEMAQUE S, PESIC A, RUSCH NJ: Vascular calcium channels and high blood pressure: pathophysiology and therapeutic implications. Vascul Pharmacol 44: 131-142, 2006.
122. STEKIEL WJ, CONTNEY SJ, LOMBARD JH: Small vessel membrane potential, sympathetic input, and electrogenic pump rate in SHR. Am J Physiol 250: C547-C556, 1986.
123. TAGUCHI K, UEDA M, KUBO T: Effects of cAMP and cGMP on L-type calcium channel currents in rat mesenteric artery cells. Jpn J Pharmacol 74: 179-186, 1997.
124. TAKATA Y, HOWES LG, HUTCHINSON JS: Antihypertensive effect of diltiazem in young or adult rats of genetically hypertensive strains. Clin Exp Hypertens A 5: 455-468, 1983.
125. TAKEMOTO M, SUN J, HIROKI J, SHIMOKAWA H, LIAO JK: Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62, 2002.
126. TANAKA Y, YAMASHITA Y, YAMAKI F, HORINOUCHI T, SHIGENOBU K, KOIKE K: MaxiK channel mediates β2-adrenoceptor-activated relaxation to isoprenaline through cAMP-dependent and -independent mechanisms in guinea-pig tracheal smooth muscle. J Smooth Muscle Res 39: 205-219, 2003.
127. 2+ channel availability in basilar artery smooth muscle cells. Pflügers Arch 433: 304-311, 1997.
128. THIBAULT C, ANAND-SRIVASTAVA MB: Altered expression of G-protein mRNA in spontaneously hypertensive rats. FEBS Lett 313: 160-164, 1992.
129. TSUDA K, MASUYAMA Y: Presynaptic regulation of neurotransmitter release in hypertension. Clin Exp Pharmacol Physiol 18: 455-467, 1991.
130. UEHATA M, ISHIZAKI T, SATOH H, ONO T, KAWAHARA T, MORISHITA T, TAMAKAWA H, YAMAGAMI K, INUI J, MAEKAWA M, NARUMIYA S: Calcium sensitization of smooth muscle mediated by a Rhoassociated protein kinase in hypertension. Nature 389: 990-994, 1997.
131. +-depolarisation and in vivo after α2-adrenoceptor stimulation. Naunyn Schmiedebergs Arch Pharmacol 322: 34-37, 1983.
132. VANHOUTTE PM: Combined alpha- and beta-adrenergic blockade in the treatment of hypertension. Introductory remarks: alpha- and beta-adrenergic receptors and the cardiovascular system. J Cardiovasc Pharmacol 3 (Suppl 1): S1-13, 1981.
133. VILLALOBOS-MOLINA R, LOPEZ-GUERRERO JJ, IBARRA M: Functional evidence of α1D-adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats. Br J Pharmacol 126: 1534-1536, 1999.
134. WESTFALL TC, MELDRUM MJ, BADINO L, EARNHARDT JT: Noradrenergic transmission in the isolated portal vein of the spontaneously hypertensive rat. Hypertension 6: 267-274, 1984.
135. WICKMAN K, CLAPHAM DE: Ion channel regulation by G proteins. Physiol Rev 75: 865-885, 1995.
136. WILLEMS WJ, HARDER DR, CONTNEY SJ, MCCUBBIN JW, STEKIEL WJ: Sympathetic supraspinal control of venous membrane potential in spontaneous hypertension in vivo. Am J Physiol 243: C101-C106, 1982.
137. WIRTH A: Rho kinase and hypertension. Biochim Biophys Acta 1802: 1276-1284, 2010.
138. WU X, SOMLYO AV, SOMLYO AP: Cyclic GMP-dependent stimulation reverses G-protein-coupled inhibition of smooth muscle myosin light chain phosphate. Biochem Biophys Res Commun 220: 658-663, 1996.
139. YAMAGUCHI I, KOPIN IJ: Blood pressure, plasma catecholamines, and sympathetic outflow in pithed SHR and WKY rats. Am J Physiol 238: H365-H372, 1980.
140. ZICHA J, KUNEŠ J: Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 79: 1227-1282, 1999.